搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
GlobalData on MSN
8 天
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
11 天
Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against ...
ThePrint on MSN
6 天
Why Indian patients groups are opposing patent requests for blockbuster HIV drug lenacapavir
Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...
12 天
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In ...
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...
newsbytesapp.com
6 天
Meet Lenacapavir: The drug that could end HIV epidemic
Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...
12 天
Gilead’s twice-yearly lenacapavir outperforms Truvada in men
If approved, lenacapavir would be the first and only twice-yearly HIV prevention choice for people who need or want PrEP.
7 天
US-based pharma giant Gilead Sciences wants HIV drug Lenacapavir patented
On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...
infectiousdiseaseadvisor.com
6 天
Twice-Yearly Injectable Lenacapavir Bests Daily PrEP Tablet for HIV Prevention
Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.
Yahoo Finance
8 天
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...
mashviral
12 天
Gilead’s Lenacapavir Halts HIV by 96%: Paves Path for FDA Approval
Gilead Sciences disclosed exceptional results from their lenacapavir injectable HIV prevention drug’s Phase 3 trial. The ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈